Tyra Biosciences, Inc. (TYRA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 9, 2026, details initial clinical results for Tyra Biosciences, Inc. The filing focuses on the SURF302 Phase 2 study evaluating oral dabogratinib for FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). Additional updates cover the SURF303 study for low-grade upper tract urothelial cancer (LG UTUC) and the BEACH301 pediatric study for achondroplasia.
Key Clinical Metrics and Financial Outlook
The filing does not provide revenue, profit, cash flow, debt, or liquidity metrics as it reports clinical milestones rather than financial performance. Key clinical metrics as of the August 31, 2026 data cutoff include:
- SURF302 (NMIBC) Efficacy (60 mg QD Cohort, n=14): Overall Response Rate (ORR) of 79% at 3 months; Complete Response (CR) of 57% at 3 months (64% Best Overall Response).
- SURF302 (NMIBC) Efficacy (50 mg QD Cohort, n=12): ORR of 67% at 3 months; CR of 33%.
- Single Marker Lesion Response (60 mg QD, n=8): 100% ORR and 63% CR at 3 months.
- Safety: Most treatment-emergent adverse events (TEAEs) were Grade 1 or 2. Grade 3 TEAEs occurred in 14% (60 mg) and 9% (50 mg) of participants. No Grade 4 or 5 TEAEs were observed. No dose reductions or treatment-related discontinuations occurred at 60 mg QD.
- Market Opportunity: Management estimates a potential total market opportunity for IR NMIBC exceeding $5 billion.
Material Changes and Strategic Updates
The filing announces the identification of 60 mg once-daily (QD) as the potential dose supporting the planned registrational adjuvant development strategy. Exposure-response analyses indicated an ORR of 86% among participants with target steady-state exposure above 2500 ng.hr/mL, compared to 58% below this threshold. Additionally, the first patient in the SURF303 study (LG UTUC) achieved a complete response at 3 months with no observed TEAEs. In the BEACH301 pediatric study, the fifth dose level was cleared with no safety signals in the safety sentinel cohort (ages 5 to 10).
Guidance, Outlook, and Risks
Tyra plans to complete enrollment in the 60 mg QD cohort and initiate a 70 mg QD cohort to explore the drug in the ablative setting. The company intends to engage health authorities on Phase 3 study design and dose selection, with a planned registrational adjuvant study expected to initiate in 2027. Management notes that approximately 70% of patients with LG IR NMIBC do not currently receive adjuvant therapy. Risks include the possibility that interim results may not predict final outcomes, potential changes in clinical outcomes as enrollment continues, and uncertainties regarding regulatory approval and market penetration.
Investor Verification Checklist
- Verify the durability of responses, noting that all 3-month CRs with 6-month assessments remained in response.
- Confirm the timeline for initiating the 70 mg QD cohort and the registrational adjuvant study in 2027.
- Monitor the exposure-response relationship data to validate the 60 mg QD dose selection for the adjuvant setting.
- Review the safety profile for long-term administration, specifically regarding transaminase TEAEs and fatigue.
- Assess the accuracy of the $5 billion market opportunity estimate against third-party market research.